



**TEXAS**  
Health and Human  
Services

**Texas Department of State  
Health Services**

January 3, 2022

Dear Therapeutic Provider:

The Texas Department of State Health Services (DSHS) would like to provide information and resources regarding the use of monoclonal antibodies in the treatment of COVID-19.

Currently, the CDC estimates that Texas and surrounding states ([Region 6](#)) have greater than 85% prevalence of the Omicron variant. Bamlanivimab/Etesevimab (BAM/ETE) and REGEN-COV (REG) are **NOT** effective in the treatment of patients infected with the Omicron variant. Sotrovimab remains effective against all variants of concern, including Omicron, but is currently in limited supply.

Providers requesting BAM/ETE and REG as therapeutic options should ensure that there is [laboratory evidence](#) that the patient is **NOT** infected by the Omicron variant. If a provider would like to request a quantity of BAM/ETE and REG to have on hand to treat a patient that is **NOT** infected by the Omicron variant according to **laboratory evidence**, please contact DSHS at [therapeutics@dshs.texas.gov](mailto:therapeutics@dshs.texas.gov).

Providers are encouraged to review the updated Food and Drug Administration (FDA) Health Care Provider Fact Sheets for [BAM/ETE](#) and [REGEN-COV](#) as they contain specific information regarding expected activity against the Omicron variant. Additionally, please continue to assess local data and review current [National Institutes of Health \(NIH\) guidelines](#) to help inform treatment decisions. Providers are invited to visit the [DSHS COVID-19 Therapeutics](#) webpage along with the recent Centers for Disease Control and Prevention [Health Alert](#).

DSHS continues to urge Texans to get vaccinated as soon as possible, get a booster shot when eligible, and to use the methods that have proven successful in weathering this epidemic: hand hygiene, distancing, improved ventilation in indoor settings, and the use of a masks in social and public environments.